Dual therapy (atazanavir/ritonavir¿+¿lamivudine) versus standard triple therapy [atazanavir/ritonavir¿+¿two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study) Academic Article 2017 uri icon

publication date

  • 2017